Watertown-based Neumora Therapeutics, a clinical-stage biopharm with a pipeline consisting of seven clinical and pre-clinical brain disease programs, has announced disappointing results from a Phase 3 study of navacaprant for the treatment of major depressive disorder (MDD). The study did not demonstrate a statistically significant improvement in MDD study participants overall. “We are disappointed by […]

Sarepta Therapeutics has inked an exclusive licensing and collaboration agreement with Arrowhead Pharmaceuticals under which Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and lungs. The agreement will add meaningfully to Sarepta’s mid- and early-stage pipeline, complementing the Company’s existing leadership in […]